Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy Updatesblue cross blue shield - louisianablue cross blue shield - louisiana Rituximab Cover…
    Ask Trek AI about this page
    Currentblue cross blue shield - louisianaPolicy MA-219

    rituximab Products

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-219 alerts

    Get alerted when Policy MA-219 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization rules for rituximab (Rituxan) and its biosimilars (Riabni, Truxima, Ruxience) for members of Blue Cross Blue Shield - Louisiana Medicare Advantage products.

    Policy Summary
    Payerblue cross blue shield - louisiana
    Policyrituximab Products
    Policy CodePolicy MA-219
    Change TypeTechnical update — no material coverage changes
    Effective DateAug 1, 2026
    Last ReviewMay 19, 2026
    Next Review DateMay 1, 2027
    Key ActionObtain prior authorization for all listed rituximab product codes before administration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All productsapplies to
    Q5115, Q5119HCPCS
    Prior authorization requiredauth required
    Acceptedbiosimilars

    Coverage Criteria for Rituximab and Biosimilars

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage criteria

    Coverage for rituximab and specific biosimilars is allowed when benefit and medical necessity criteria are met; preferred and non-preferred distinctions apply.

    General coverage prerequisites: Benefits must be available in the member's contract/certificate AND medical necessity criteria and guidelines must be met.
    Covered products: Based on review of available data, the Health Plan may consider rituximab (Rituxan) and rituximab-arrx (Riabni) to be eligible for coverage; the Health Plan may consider the use of rituximab-abbs (Truxima) and rituximab-pvvr (Ruxience) to be eligible for coverage when patient selection criteria are met.
    Patient selection for non-preferred biosimilars: Patient has tried and failed (e.g., intolerance or inadequate response) BOTH rituximab (Rituxan) AND rituximab-arrx (Riabni) for at least TWO months EACH unless there is clinical evidence or patient history that suggests these products will be ineffective or cause an adverse reaction.two months on each product

    This is a required prior trial before coverage of Truxima or Ruxience unless contraindicated.

    Use of rituximab-abbs (Truxima) or rituximab-pvvr (Ruxience) is considered not medically necessary when the patient selection criterion is not met. Specifically, these non-preferred biosimilars require prior trial and failure of the preferred rituximab products before they will be considered for coverage.

    The Health Plan considers use of rituximab-abbs (Truxima) or rituximab-pvvr (Ruxience) not medically necessary when the documented patient selection requirement — trial and failure of both Rituxan and Riabni — has not been satisfied.

    Initial Therapy Requirements

    Initial therapy requirements for Truxima and Ruxience

    Patient selection for non-preferred biosimilars

    Required prior trials before non-preferred biosimilar: Patient has tried and failed BOTH rituximab (Rituxan) AND rituximab-arrx (Riabni) for at least TWO months EACH unless there is clinical evidence or patient history suggesting ineffectiveness or adverse reaction.two months on each product

    This functions as a step requirement prior to coverage of Truxima or Ruxience.

    Step Therapy / Required Trials

    StepRequirementDuration/ThresholdCoverage status
    1Patient must trial and fail BOTH rituximab (Rituxan) and rituximab-arrx (Riabni)At least TWO months on each product unless clinical evidence or patient history indicates likely ineffectiveness or adverse reactionCoverage of rituximab-abbs (Truxima) or rituximab-pvvr (Ruxience)

    HCPCS, CPT, and Diagnosis Codes

    HCPCS CodesHCPCS
    Q5115
    Q5119
    ICD-10 DiagnosisICD-10
    All Related Diagnoses
    CPTCPT
    No codes

    Prior Authorization and Provider Requirements

    Prior Authorization

    Prior authorization required for all listed codes

    All codes listed on this Medical Policy require prior authorization to ensure appropriate utilization and alignment with current clinical guidelines.

    • HCPCS codes listed for rituximab products include Q5115 and Q5119; prior authorization applies to these codes.
    Step Therapy

    Require trials of Rituxan and Riabni before non‑preferred biosimilars

    Coverage for rituximab-abbs (Truxima) and rituximab-pvvr (Ruxience) will be considered only after the patient has tried and failed BOTH rituximab (Rituxan) AND rituximab-arrx (Riabni) for at least two months each, unless clinical evidence or patient history indicates likely ineffectiveness or adverse reaction.

    • Failure may include intolerance or inadequate response.
    • Each preferred product must be used for at least two months prior to considering the biosimilar.
    Documentation Required

    Provide prior‑plan authorization documentation for 90‑day transitions

    When honoring a prior authorization from a previous health plan during a 90-day transition, documentation of the previous plan’s authorization for the ongoing course of treatment must be provided by the member or their provider.

    • Services must otherwise be covered under the Blue Advantage health plan for the transition to apply.
    • This applies to ongoing courses of treatment and is limited to a 90-day transition period.
    Denial Risk

    Risk of denial if prior trials of preferred products are not documented

    Use of rituximab-abbs (Truxima) or rituximab-pvvr (Ruxience) is considered not medically necessary when the required patient selection criterion (failure of both Rituxan and Riabni) is not met; requests lacking documented trials and failures of the preferred products risk denial.

    • Denial risk applies if intolerance/inadequate response to both preferred products is not documented.
    • Ensure chart documentation shows at least two months of therapy and evidence of failure for each preferred product when requesting coverage for Truxima or Ruxience.

    Biosimilar Coverage Notes

    Billing Rule

    Non-preferred biosimilars require prior failure of Rituxan and Riabni

    Coverage for non-preferred biosimilars (Truxima, Ruxience) is allowed only after documented failure of both Rituxan and Riabni for at least two months each, unless there is clinical evidence or patient history indicating ineffectiveness or adverse reaction.

    • Required trial duration: ≥ two months on each preferred product
    • Failure criteria: intolerance or inadequate response
    Documentation Required

    Document prior trials of Rituxan and Riabni before coverage

    Requests for Truxima or Ruxience must document prior trials showing failure of both Rituxan and Riabni for at least two months each, unless contraindicated by clinical evidence or patient history.

    • Document duration and reason for discontinuation (intolerance or inadequate response) for each prior product
    Note

    Riabni eligible for coverage alongside Rituxan

    Riabni (rituximab-arrx) is considered an eligible product for coverage alongside Rituxan as a preferred/covered option.

    • Riabni is recognized as a biosimilar to Rituxan with no clinically meaningful differences

    Infusion and Site-of-Care Considerations

    Note

    Provide rituximab infusions in an infusion center

    Infusion services for rituximab products are expected to be provided in an infusion center setting as indicated by the policy coding and site-of-care guidance.

    • Site of care listed: infusion center

    Definitions

    Biosimilar
    DefinitionBiosimilar: a biological product highly similar to and with no clinically meaningful differences from an existing FDA-approved reference product.
    Rituximab reference productRituxan is the FDA-approved reference product for rituximab biosimilars.
    Example biosimilarsRiabni, Truxima, and Ruxience are identified as rituximab biosimilar products.
    Regulatory standardBiosimilars meet the FDA's rigorous standards for approval and have established safety and effectiveness for labeled indications.
    Coverage noteCoverage of an FDA-approved biosimilar as an alternate to the reference product is not considered step therapy by the Health Plan.

    Background

    Rituximab is an anti-CD20 monoclonal antibody that targets CD20+ B-cells to reduce B-cell numbers in lymphomas and autoimmune diseases thought to be B-cell mediated. Biosimilars such as Riabni, Truxima, and Ruxience are biological products highly similar to the FDA-approved reference product (Rituxan) and are considered to have no clinically meaningful differences for labeled indications.

    Policy Summary
    Payerblue cross blue shield - louisiana
    Policyrituximab Products
    Policy CodePolicy MA-219
    Change TypeTechnical update — no material coverage changes
    Effective DateAug 1, 2026
    Last ReviewMay 19, 2026
    Next Review DateMay 1, 2027
    Key ActionObtain prior authorization for all listed rituximab product codes before administration.
    SourceLink
    On This Page
    Coverage Criteria for Rituximab and BiosimilarsInitial Therapy RequirementsStep Therapy / Required TrialsHCPCS, CPT, and Diagnosis CodesPrior Authorization and Provider RequirementsBiosimilar Coverage NotesInfusion and Site-of-Care ConsiderationsDefinitionsBackground